ATRX guards against aberrant differentiation in mesenchymal progenitor cells
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Yan Fang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA. Hauptthemen laut MEDLINE: Cell Differentiation, Heterochromatin, Mesenchymal Stem Cells, X-linked Nuclear Protein. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Damon Runyon Cancer Research Foundation.
Abstract (Originalsprache)
Alterations in the tumor suppressor ATRX are recurrently observed in mesenchymal neoplasms. ATRX has multiple epigenetic functions including heterochromatin formation and maintenance and regulation of transcription through modulation of chromatin accessibility. Here, we show in murine mesenchymal progenitor cells (MPCs) that Atrx deficiency aberrantly activated mesenchymal differentiation programs. This includes adipogenic pathways where ATRX loss induced expression of adipogenic transcription factors and enhanced adipogenic differentiation in response to differentiation stimuli. These changes are linked to loss of heterochromatin near mesenchymal lineage genes together with increased chromatin accessibility and gains of active chromatin marks. We additionally observed depletion of H3K9me3 at transposable elements, which are derepressed including near mesenchymal genes where they could serve as regulatory elements. Finally, we demonstrated that loss of ATRX in a mesenchymal malignancy, undifferentiated pleomorphic sarcoma, results in similar epigenetic disruption and de-repression of transposable elements. Together, our results reveal a role for ATRX in maintaining epigenetic states and transcriptional repression in mesenchymal progenitors and tumor cells and in preventing aberrant differentiation in the progenitor context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA.
- Laboratory of Chromatin Biology and Epigenetics, The Rockefeller University, New York, NY 10065, USA.
- Bioinformatics Resource Center, The Rockefeller University, New York, NY10065, USA.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA.
ORCID-Profile: Benjamin A Nacev
Förderung
- NIH HHS
- NCI NIH HHS
- Damon Runyon Cancer Research Foundation
- Connective Tissue Oncology Society
- NIH
Zitieren
APA
Fang, Y., Barrows, D., Dabas, Y., Carroll, T. S., Singer, S., Tap, W. D., & Nacev, B. A. (2024). ATRX guards against aberrant differentiation in mesenchymal progenitor cells. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae160
Vancouver
Fang Y, Barrows D, Dabas Y, Carroll TS, Singer S, Tap WD, et al. ATRX guards against aberrant differentiation in mesenchymal progenitor cells. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae160
BibTeX
@article{Fang2024,
author = {Fang, Yan and Barrows, Douglas and Dabas, Yakshi and Carroll, Thomas S and Singer, Sam and Tap, William D and Nacev, Benjamin A},
title = {ATRX guards against aberrant differentiation in mesenchymal progenitor cells},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae160}
}
EUVIMED